Literature DB >> 23832945

Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism.

Melanie Hutter1, Bjoern Moosmann, Stefan Kneisel, Volker Auwärter.   

Abstract

Aminoalkylindoles, a subclass of synthetic cannabinoid receptor agonists, show an extensive and complex metabolism in vivo, and due to their structural similarity, they can be challenging in terms of unambiguous assignment of metabolic patterns in urine samples to consumed substances. The situation may even be more complicated as these drugs are usually smoked, and the high temperature exposure may lead to formation of artifacts. Typical metabolites of JWH-018 (Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone) were reportedly detected not only in urine samples collected after consumption of JWH-018 but also after AM-2201 (1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone) use. The aim of the presented study was to evaluate if typical JWH-018 metabolites can be formed metabolically in humans and if JWH-018 may be formed artifactually during smoking of AM-2201. Therefore, one of the authors ingested 5 mg of pure AM-2201, and serum as well as urine samples were analyzed subsequently. Additionally, the smoke condensate from a cigarette laced with pure AM-2201 was investigated. In addition, urine samples of patients after known consumption of AM-2201 or JWH-018 were evaluated. The results of the study prove that typical metabolites of JWH-018 and JWH-073 are built in humans after ingestion of AM-2201. However, the N-(4-hydroxypentyl) metabolite of JWH-018, which is the major metabolite after JWH-018 use, was not detected after the self-experiment. In the smoke condensate, small amounts of JWH-018 and JWH-022 (Naphthalen-1-yl[1-(pent-4-en-1-yl)-1H-indol-3-yl]methanone) were detected. Nevertheless, the results of our study suggest that the amounts absorbed by smoking do not significantly influence the metabolic pattern in urine samples. Therefore, the N-(4-hydroxypentyl) metabolite of JWH-018 can serve as a valuable marker to distinguish consume of products containing AM-2201 from JWH-018 use.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  AM-2201; JWH-018; JWH-022; Spice; metabolism; smoke condensate; synthetic cannabinoid

Mesh:

Substances:

Year:  2013        PMID: 23832945     DOI: 10.1002/jms.3229

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  19 in total

1.  High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS.

Authors:  Kei Zaitsu; Hiroshi Nakayama; Mayumi Yamanaka; Kazuaki Hisatsune; Kentaro Taki; Tomomi Asano; Tooru Kamata; Munehiro Katagai; Yumi Hayashi; Maiko Kusano; Hitoshi Tsuchihashi; Akira Ishii
Journal:  Int J Legal Med       Date:  2015-09-08       Impact factor: 2.686

2.  Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA.

Authors:  Ariane Wohlfarth; Marisol S Castaneto; Mingshe Zhu; Shaokun Pang; Karl B Scheidweiler; Robert Kronstrand; Marilyn A Huestis
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

3.  Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes.

Authors:  Jeremy Carlier; Xingxing Diao; Cristina Sempio; Marilyn A Huestis
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

4.  Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats.

Authors:  Jeremy Carlier; Ariane Wohlfarth; Bonita D Salmeron; Karl B Scheidweiler; Marilyn A Huestis; Michael H Baumann
Journal:  J Pharmacol Exp Ther       Date:  2018-09-28       Impact factor: 4.030

5.  Structural Elucidation of Metabolites of Synthetic Cannabinoid UR-144 by Cunninghamella elegans Using Nuclear Magnetic Resonance (NMR) Spectroscopy.

Authors:  Shimpei Watanabe; Unnikrishnan Kuzhiumparambil; Shanlin Fu
Journal:  AAPS J       Date:  2018-03-08       Impact factor: 4.009

6.  Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens.

Authors:  Marisol S Castaneto; Karl B Scheidweiler; Adarsh Gandhi; Ariane Wohlfarth; Kevin L Klette; Thomas M Martin; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-09-17       Impact factor: 3.345

7.  Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry.

Authors:  Jeremy Carlier; Karl B Scheidweiler; Ariane Wohlfarth; Bonita D Salmeron; Michael H Baumann; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2016-05-06       Impact factor: 4.759

8.  Analysis of Parent Synthetic Cannabinoids in Blood and Urinary Metabolites by Liquid Chromatography Tandem Mass Spectrometry.

Authors:  Jessica L Knittel; Justin M Holler; Jeffrey D Chmiel; Shawn P Vorce; Joseph Magluilo; Barry Levine; Gerardo Ramos; Thomas Z Bosy
Journal:  J Anal Toxicol       Date:  2016-01-19       Impact factor: 3.367

9.  Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS.

Authors:  Ariane Wohlfarth; Shaokun Pang; Mingshe Zhu; Adarsh S Gandhi; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Bioanalysis       Date:  2014-05       Impact factor: 2.681

10.  High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes.

Authors:  Adarsh S Gandhi; Ariane Wohlfarth; Mingshe Zhu; Shaokun Pang; Marisol Castaneto; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2014-05-14       Impact factor: 3.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.